{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:40Z","timestamp":1787009980630,"version":"build-2736575974"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/gme.0b013e31829755ed","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T11:04:02Z","timestamp":1372763042000},"page":"309-319","source":"Crossref","is-referenced-by-count":40,"title":["Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy"],"prefix":"10.1097","volume":"21","author":[{"given":"JoAnn V.","family":"Pinkerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Z.","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210211","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/gme.0b013e31821f92df","article-title":"Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.","volume":"19","author":"Tan","year":"2012","journal-title":"Menopause"},{"key":"R2-20-20210211","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1743-6109.2009.01335.x","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women.","volume":"6","author":"Santoro","year":"2009","journal-title":"J Sex Med"},{"key":"R3-20-20210211","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1089\/jwh.2010.2151","article-title":"Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen.","volume":"20","author":"Simon","year":"2011","journal-title":"J Womens Health (Larchmt)"},{"issue":"suppl 1","key":"R6-20-20210211","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1210\/jc.2009-2509","article-title":"Postmenopausal hormone therapy: an Endocrine Society scientific statement.","volume":"95","author":"Santen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20-20210211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13697130802585576","article-title":"Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.","volume":"12","author":"Al-Baghdadi","year":"2009","journal-title":"Climacteric"},{"key":"R8-20-20210211","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.fertnstert.2005.06.042","article-title":"A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women.","volume":"85","author":"Long","year":"2006","journal-title":"Fertil Steril"},{"key":"R9-20-20210211","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 hormone therapy position statement of: The North American Menopause Society.","volume":"19","year":"2012","journal-title":"Menopause"},{"key":"R10-20-20210211","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/gme.0b013e3182518e9a","article-title":"The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005 estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.","volume":"19","author":"Cano","year":"2012","journal-title":"Menopause"},{"key":"R11-20-20210211","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/gme.0b013e31817b6132","article-title":"Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"R12-20-20210211","first-page":"431","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action.","volume":"295","author":"Dutertre","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-20-20210211","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1091\/mbc.e03-06-0360","article-title":"Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors and.","volume":"15","author":"Tee","year":"2004","journal-title":"Mol Biol Cell"},{"key":"R16-20-20210211","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-200342040-00004","article-title":"Pharmacokinetics of selective estrogen receptor modulators.","volume":"42","author":"Morello","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R17-20-20210211","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/17425255.2010.487483","article-title":"Pharmacologic evaluation of ospemifene.","volume":"6","author":"McCall","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R19-20-20210211","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/13697130802657896","article-title":"Pharmacology and clinical applications of selective estrogen receptor modulators.","volume":"12","author":"Nath","year":"2009","journal-title":"Climacteric"},{"key":"R20-20-20210211","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2165\/00003088-198815030-00003","article-title":"Clinical pharmacokinetics of drugs used in the treatment of breast cancer.","volume":"15","author":"Wiebe","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"R21-20-20210211","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2125.2006.02709.x","article-title":"Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.","volume":"63","author":"Ouellet","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20-20210211","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1021\/jm980048b","article-title":"Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonistantagonist, CP-336156, a diaryltetrahydronaphthalene.","volume":"41","author":"Rosati","year":"1998","journal-title":"J Med Chem"},{"key":"R23-20-20210211","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0009-9236(03)90527-3","article-title":"Bazedoxifene acetate dose proportionality in healtly, postmenopausal women.","volume":"73","author":"Ermer","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20-20210211","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0009-9236(03)90515-7","article-title":"Absoluterelative bioavailability of bazedoxifene acetate in health postmenopausal women.","volume":"73","author":"Patat","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20-20210211","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1124\/dmd.108.021808","article-title":"Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys.","volume":"36","author":"Prakash","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R27-20-20210211","first-page":"448","article-title":"Ospemifene Hormos.","volume":"5","author":"Gennari","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"R28-20-20210211","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.54.1.105","article-title":"Differential response of estrogen receptor and estrogen receptor to partial estrogen agonistsantagonists.","volume":"54","author":"Barkhem","year":"1998","journal-title":"Mol Pharmacol"},{"key":"R29-20-20210211","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/00365519850186670","article-title":"Thyroid function in postmenopausal breast cancer patients treated with tamoxifen.","volume":"58","author":"Anker","year":"1998","journal-title":"Scand J Clin Lab Invest"},{"key":"R30-20-20210211","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/1471-2407-10-313","article-title":"Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.","volume":"10","author":"Gjerde","year":"2010","journal-title":"BMC Cancer"},{"key":"R31-20-20210211","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0015-0282(02)03288-0","article-title":"Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity.","volume":"78","author":"Reindollar","year":"2002","journal-title":"Fertil Steril"},{"key":"R32-20-20210211","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"key":"R33-20-20210211","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"key":"R34-20-20210211","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/endo.139.4.5902","article-title":"Effects of CP-336,156, a new, nonsteroidal estrogen agonistantagonist, on bone, serum cholesterol, uterus and body composition in rat models.","volume":"139","author":"Ke","year":"1998","journal-title":"Endocrinology"},{"key":"R35-20-20210211","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0091270005283280","article-title":"Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.","volume":"46","author":"Gardner","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R36-20-20210211","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1021\/jm010086m","article-title":"Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.","volume":"44","author":"Miller","year":"2001","journal-title":"J Med Chem"},{"issue":"suppl 5","key":"R37-20-20210211","first-page":"s19","article-title":"Efficacy of bazedoxifene, pre-bisphosphonate sequential therapy for osteoporosis and the patient profile for bazedoxifene.","volume":"2","author":"Palacios","year":"2010","journal-title":"Rev Osteoporos Metab Miner"},{"key":"R38-20-20210211","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women.","volume":"24","author":"Komi","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"R39-20-20210211","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","article-title":"Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women.","volume":"18","author":"Komi","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"R40-20-20210211","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis.","volume":"362","author":"Cummings","year":"2010","journal-title":"N Engl J Med"},{"key":"R41-20-20210211","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R42-20-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1759720X11422602","article-title":"Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis.","volume":"4","author":"Komm","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R43-20-20210211","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: progress and future perspectives.","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"R44-20-20210211","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/humupd\/6.3.255","article-title":"Skeletal effects of selective oestrogen receptor modulators (SERMs).","volume":"6","author":"Diez","year":"2000","journal-title":"Hum Reprod Update"},{"key":"R46-20-20210211","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group.","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"R47-20-20210211","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"R48-20-20210211","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"R49-20-20210211","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer.","volume":"77","author":"Taras","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R50-20-20210211","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/gme.0b013e318223e82a","article-title":"Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model.","volume":"19","author":"Burich","year":"2012","journal-title":"Menopause"},{"key":"R51-20-20210211","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/01.CIR.0000154545.84124.AC","article-title":"Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.","volume":"111","author":"Decensi","year":"2005","journal-title":"Circulation"},{"key":"R52-20-20210211","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"R53-20-20210211","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R54-20-20210211","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"R55-20-20210211","first-page":"937","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen.","volume":"18","author":"Braithwaite","year":"2003","journal-title":"JGen Intern Med"},{"key":"R57-20-20210211","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/CIRCULATIONAHA.108.817577","article-title":"Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.","volume":"119","author":"Collins","year":"2009","journal-title":"Circulation"},{"key":"R58-20-20210211","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/CIRCULATIONAHA.109.924571","article-title":"Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.","volume":"122","author":"Ensrud","year":"2010","journal-title":"Circulation"},{"key":"R60-20-20210211","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/glia.20904","article-title":"Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro.","volume":"58","author":"Cerciat","year":"2010","journal-title":"Glia"},{"key":"R61-20-20210211","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/neu.20043","article-title":"Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol.","volume":"61","author":"Ciriza","year":"2004","journal-title":"J Neurobiol"},{"key":"R62-20-20210211","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/gme.0b013e3181c4f1d6","article-title":"Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.","volume":"17","author":"Pinkerton","year":"2010","journal-title":"Menopause"},{"key":"R64-20-20210211","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1067\/mob.2003.374","article-title":"Short-term urogenital effects ofraloxifene, tamoxifen, and estrogen.","volume":"189","author":"Vardy","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R65-20-20210211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"key":"R66-20-20210211","first-page":"645","article-title":"Vaginal effects of lasofoxifene and raloxifene: preliminary evidence suggests lasofoxifene, but not raloxifene, improves indices of vaginal health (Abstract P-87).","volume":"11","author":"Portman","year":"2004","journal-title":"Menopause"},{"key":"R67-20-20210211","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejogrb.2008.01.017","article-title":"Effect of raloxifene on the vaginal epithelium of postmenopausal women.","volume":"139","author":"Delmanto","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R68-20-20210211","first-page":"258","article-title":"Effects of tamoxifen on the human female genital tract: review of the literature.","volume":"24","author":"Varras","year":"2003","journal-title":"Eur J Gynaecol Oncol"},{"key":"R69-20-20210211","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1054\/bjoc.2001.1703","article-title":"Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.","volume":"84","author":"Marttunen","year":"2001","journal-title":"Br J Cancer"},{"key":"R70-20-20210211","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/jwh.2011.3448","article-title":"The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.","volume":"21","author":"Kagan","year":"2012","journal-title":"J Womens Health (Larchmt)"},{"key":"R71-20-20210211","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifeneconjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"key":"R72-20-20210211","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1067\/mob.2002.123938","article-title":"Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study.","volume":"187","author":"Goldstein","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R73-20-20210211","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/gme.0b013e318223bbf4","article-title":"Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.","volume":"19","author":"Goldstein","year":"2012","journal-title":"Menopause"},{"key":"R74-20-20210211","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1102\/1470-7330.2008.0020","article-title":"The effect of tamoxifen on the genital tract.","volume":"8","author":"Polin","year":"2008","journal-title":"Cancer Imaging"},{"key":"R75-20-20210211","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000225571","article-title":"Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients.","volume":"38","author":"Boccardo","year":"1981","journal-title":"Oncology"},{"key":"R76-20-20210211","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO.1999.17.5.1488","article-title":"Effect of tamoxifen on sexual functioning in patients with breast cancer.","volume":"17","author":"Mortimer","year":"1999","journal-title":"J Clin Oncol"},{"key":"R77-20-20210211","first-page":"346","article-title":"Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy.","volume":"101","author":"Parsons","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R78-20-20210211","first-page":"45","article-title":"Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.","volume":"10","author":"Pinkerton","year":"2003","journal-title":"Menopause"},{"key":"R79-20-20210211","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/cmt.6.3.248.256","article-title":"Effect of raloxifene on sexual function in postmenopausal women.","volume":"6","author":"Kessel","year":"2003","journal-title":"Climacteric"},{"issue":"pt 1","key":"R80-20-20210211","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0b013e318031a83d","article-title":"The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.","volume":"14","author":"Stovall","year":"2007","journal-title":"Menopause"},{"key":"R81-20-20210211","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13697130701379311","article-title":"The long-term effect of raloxifene on the genitourinary tract.","volume":"10","author":"Sharma","year":"2007","journal-title":"Climacteric"},{"key":"R82-20-20210211","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex containing bazedoxifeneconjugated estrogens as a menopausal therapy.","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil Steril"},{"key":"R83-20-20210211","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifeneconjugated estrogens for treatment of moderate to severe vulvarvaginal atrophy in postmenopausal women.","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"key":"R85-20-20210211","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jbmr.191","article-title":"Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.","volume":"26","author":"Cummings","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"suppl 1","key":"R86-20-20210211","first-page":"92","article-title":"Efficacy of ospemifene when used in the treatment of vulvar and vaginal atrophy for up to 52 weeks in postmenopausal women.","volume":"14","author":"Bachmann","year":"2011","journal-title":"Climacteric"},{"issue":"suppl 1","key":"R87-20-20210211","first-page":"87","article-title":"Evaluation of the safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women.","volume":"14","author":"Simon","year":"2011","journal-title":"Climacteric"},{"key":"R88-20-20210211","first-page":"1343","article-title":"Efficacy of a novel SERM, ospemifene, in the treatment of moderate-to-severe vaginal dryness symptoms of vulvovaginal atrophy associated with menopause (Abstract).","volume":"18","author":"Portman","year":"2011","journal-title":"Menopause"},{"key":"R90-20-20210211","first-page":"1228","article-title":"Vaginal effects of lasofoxifene: 3-year results from the PEARL trial (Abstract LB-5).","volume":"15","author":"Goldstein","year":"2008","journal-title":"Menopause"},{"key":"R91-20-20210211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/gme.0b013e3181e84bb4","article-title":"Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial: 5-year gynecological outcomes.","volume":"18","author":"Goldstein","year":"2011","journal-title":"Menopause"},{"key":"R92-20-20210211","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00042192-200512020-00020","article-title":"Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM), improves dysparenunia in postmenopausal women with vaginal atrophy (VA).","volume":"12","author":"Bachmann","year":"2005","journal-title":"Menopause"},{"key":"R95-20-20210211","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4088\/JCP.v69n0208","article-title":"Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment.","volume":"69","author":"Janicak","year":"2008","journal-title":"J Clin Psychiatry"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GME.0b013e31829755ed","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:42:40Z","timestamp":1620938560000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201403000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e31829755ed","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}